Major depressive disorder There has been much debate as to whether<unk>  is more efficacious than placebo in the treatment of depression. According to a 2009 meta-analysis of 12 second-generation antidepressants,<unk>  was no more effective than placebo, and was "significantly less" effective, and less acceptable, than the other drugs in treating the acute-phase of adults with unipolar major depression. The British MHRA said in September 2011 that the study had several limitations, and that "Overall the balance of benefits and risks for<unk>  remains positive in its authorised indication." A UK and Europe-wide review of available efficacy and safety data has confirmed that<unk>  has benefit over placebo in its authorised indication. Efficacy was clearly shown in patients with severe or very severe depression. According to a systematic review and meta-analysis by IQWiG, including unpublished data, published data on<unk>  overestimated the benefit of<unk>  versus placebo by up to 115% and<unk>  versus SSRIs by up to 23%, and also underestimated harm, concluding that<unk>  was an ineffective and potentially harmful antidepressant. The study also showed that nearly three quarters of the data on patients who took part in trials of<unk>  had not been published by Pfizer. A 2018 systematic review and network meta-analysis comparing the efficacy and acceptability of 21 antidepressant drugs concluded that<unk>  was significantly less efficacious than other antidepressants tested. Panic disorder In a randomised double-blind placebo-controlled trial<unk>  significantly improved the symptoms of panic disorder. Another randomised controlled trial that compared paroxetine to<unk>  found that paroxetine significantly outperformed<unk>  as a treatment for panic disorder. Despite this discouraging finding an open-label trial examining the efficacy of<unk>  in SSRI-resistant panic disorder demonstrated significant benefit from<unk>  treatment. Attention deficit hyperactivity disorder Numerous clinical trials have provided support for the efficacy of<unk>  in the treatment of attention deficit hyperactivity disorder (ADHD) in both the short and long-term and in both children/adolescents and adults. Other uses A case series and open-label pilot study demonstrated the efficacy of<unk>  in treating bulimia nervosa.<unk>  may also have efficacy in treating therapy-resistant paediatric nocturnal enuresis. A pilot study demonstrated the efficacy of<unk>  in the treatment of narcolepsy. Individual trials and meta-analysis suggest that<unk>  can attenuate antipsychotic-induced weight gain and there is some evidence of a benefit on depressive, and possibly other symptoms of schizophrenia when added to antipsychotic treatment.
Reboxetine
Fluoxetine
Dapoxetine
Duloxetine
Paroxetine
Atomoxetine
Nabilone
Vinpocetine